MUC1‐C oncoprotein confers androgen‐independent growth of human prostate cancer cells
- 2 April 2012
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 72 (15), 1659-1668
- https://doi.org/10.1002/pros.22519
Abstract
BACKGROUND The mucin 1 (MUC1) heterodimeric oncoprotein is overexpressed in human prostate cancers with aggressive pathologic and clinical features. However, few insights are available regarding the functional role of MUC1 in prostate cancer. METHODS Effects of MUC1‐C on androgen receptor (AR) expression were determined by RT‐PCR, immunoblotting and AR promoter activation. Coimmunoprecipitations, direct binding assays, and chromatin immunoprecipitation (ChIP) studies were performed to assess the interaction between MUC1‐C and AR. Cells were analyzed for invasion, growth in androgen‐depleted medium, and sensitivity to MUC1‐C inhibitors. RESULTS The present studies in androgen‐dependent LNCaP and LAPC4 prostate cancer cells demonstrate that the oncogenic MUC1‐C subunit suppresses AR expression. The results show that MUC1‐C activates a posttranscriptional mechanism involving miR‐135b‐mediated downregulation of AR mRNA levels. The results further demonstrate that MUC1‐C forms a complex with AR through a direct interaction between the MUC1‐C cytoplasmic domain and the AR DNA‐binding domain (DBD). In addition, MUC1‐C associates with AR in a complex that occupies the PSA promoter. The interaction between MUC1‐C and AR is associated with induction of the epithelial‐mesenchymal transition (EMT) and increased invasion. MUC1‐C also conferred growth in androgen‐depleted medium and resistance to bicalutamide treatment. Moreover, expression of MUC1‐C resulted in sensitivity to the MUC1‐C inhibitor GO‐203 with inhibition of growth in vitro. GO‐203 treatment also inhibited growth of established tumor xenografts in nude mice. CONCLUSIONS These findings indicate that MUC1‐C suppresses AR expression in prostate cancer cells and confers a more aggressive androgen‐independent phenotype that is sensitive to MUC1‐C inhibition. Prostate 72:1659–1668, 2012.Keywords
This publication has 51 references indexed in Scilit:
- New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling PathwayClinical Cancer Research, 2011
- PrLZ Protects Prostate Cancer Cells from Apoptosis Induced by Androgen Deprivation via the Activation of Stat3/Bcl-2 PathwayCancer Research, 2011
- Oncogenic function of the MUC1 receptor subunit in gene regulationOncogene, 2010
- The Role of microRNA-221 and microRNA-222 in Androgen-Independent Prostate Cancer Cell LinesCancer Research, 2009
- The MUC1 and Galectin-3 Oncoproteins Function in a MicroRNA-Dependent Regulatory LoopMolecular Cell, 2007
- Nuclear Import of the MUC1-C Oncoprotein Is Mediated by Nucleoporin Nup62Online Journal of Public Health Informatics, 2007
- Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?Nature Reviews Cancer, 2007
- Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling AxisJournal of Clinical Oncology, 2005
- Gene expression profiling identifies clinically relevant subtypes of prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2004
- Human DF3/MUC1 carcinoma-associated protein functions as an oncogeneOncogene, 2003